Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation

Tsuji, Shintaro; Ishikawa, Tomoki; Morii, Yasuhiro; Zhang, Hongjian; Suzuki, Teppei; Tanikawa, Takumi; Nakaya, Jun; Ogasawara, Katsuhiko

Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation

Tsuji, Shintaro; Ishikawa, Tomoki; Morii, Yasuhiro et al.

Journal of medical internet research, 2020, 22(9), e16053

Permalink : https://hdl.handle.net/2115/80263

このアイテムのアクセス数:549件（2026-10-16 07:46 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.2196/16053			75

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/80263
タイトル	Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
著者	Tsuji, Shintaro ; Ishikawa, Tomoki ; Morii, Yasuhiro ; Zhang, Hongjian ; Suzuki, Teppei ; Tanikawa, Takumi ; Nakaya, Jun ; Ogasawara, Katsuhiko
著者名 Tsuji, Shintaro
e-Rad_Researcher 90802661 著者名 Ishikawa, Tomoki
e-Rad_Researcher 70880574 著者名 Morii, Yasuhiro
著者名 Zhang, Hongjian
著者名 Suzuki, Teppei
e-Rad_Researcher 40446539 著者名 Tanikawa, Takumi
著者名 Nakaya, Jun
e-Rad_Researcher 90322859 著者名 Ogasawara, Katsuhiko
言語	英語
キーワード	Markov model
	telehealth
	continuous glucose monitoring (CGM)
	type 2 diabetes mellitus
	cost-effectiveness
	incremental cost and effective ratio (ICER)
発行日	2020-09-17
出版者	Journal of Medical Internet Research（JMIR）
収録物名	Journal of medical internet research
巻(号)	22(9)
ページ	e16053
抄録	Background: Apps for real-time continuous glucose monitoring (CGM) on smartphones and other devices linked to CGM systems have recently been developed, and such CGM apps are also coming into use in Japan. In comparison with conventional retrospective CGM, the use of CGM apps improves patients' own blood glucose control, which is expected to help slow the progression of type 2 diabetes mellitus (DM) and prevent complications, but the effect of their introduction on medical costs remains unknown. Objective: Our objective in this study was to perform an economic appraisal of CGM apps from the viewpoint of assessing public medical costs associated with type 2 DM, using the probability of developing type 2 DM-associated complications, and data on medical costs and utility value to carry out a medical cost simulation using a Markov model in order to ascertain the cost-effectiveness of the apps. Methods: We developed a Markov model with the transition states of insulin therapy, nephrosis, dialysis, and cardiovascular disease, all of which have a major effect on medical costs, to identify changes in medical costs and utility values resulting from the introduction of a CGM app and calculated the incremental cost-effectiveness ratio (ICER). Results: The ICER for CGM app use was US $33,039/quality-adjusted life year (QALY). Conclusions: Sensitivity analyses showed that, with the exception of conditions where the transition probability of insulin therapy, utility value, or increased medical costs increases, the ICER for the introduction of CGM apps was below the threshold of US $43,478/QALY used by the Central Social Insurance Medical Council. Our results provide basic data on the cost-effectiveness of introducing CGM apps, which are currently starting to come into use.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
PISSN	1438-8871
関連情報	PMID 32940613
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.2196/16053